Older adults taking GLP-1 receptor agonists, primarily semaglutide (Rybelsus, Ozempic, Wegovy), had a small uptick in their ...

Novo Nordisk's popular weight-loss and diabetes drugs Wegovy and Ozempic may in very rare cases cause a serious eye condition ...

Treatment should be stopped if nonarteritic anterior ischemic optic neuropathy, which can cause vision loss, is diagnosed.

European Medicines Agency (EMA)'s safety committee (PRAC) has concluded its review of medicines containing semaglutide ...

By pairing semaglutide with one or two experimental antibodies designed to preserve muscle, participants lost less lean body ...

A potentially blinding condition is a very rare side effect of the GLP-1 receptor agonist semaglutide (Ozempic, Wegovy, ...

The following is a summary of “Association of Glucagon-like Peptide-1 Receptor Agonists with Optic Nerve and Retinal Adverse ...

A new study has found a significant association between the use of GLP-1s such as Ozempic and Wegovy with a higher risk of developing a serious eye condition in patients with diabetes. Here are four t ...

Interim results from the Phase II COURAGE trial show that combining semaglutide with anti-GDF8 antibody trevogrumab preserves ...

Researchers have zeroed in on yet another possible ocular concern for diabetes patients who take popular GLP-1 therapies in a ...

A popular weight-loss drug may be changing how doctors treat obesity—but scientists are just starting to uncover exactly how ...

Given the evidence, the committee has recommended that the labels for Novo Nordisk’s Wegovy and Ozempic be updated to include ...